Compare VNDA & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNDA | TKNO |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.4M | 308.3M |
| IPO Year | 2005 | 2021 |
| Metric | VNDA | TKNO |
|---|---|---|
| Price | $6.26 | $5.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.90 | N/A |
| AVG Volume (30 Days) | ★ 905.2K | 228.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $216,105,000.00 | $40,520,000.00 |
| Revenue This Year | $21.35 | $8.27 |
| Revenue Next Year | $37.40 | $13.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.72 | 7.35 |
| 52 Week Low | $4.14 | $1.91 |
| 52 Week High | $9.91 | $6.68 |
| Indicator | VNDA | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 55.21 |
| Support Level | $5.97 | $4.79 |
| Resistance Level | $6.73 | $5.84 |
| Average True Range (ATR) | 0.21 | 0.43 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 54.72 | 43.93 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.